...
首页> 外文期刊>Journal of Clinical Microbiology >Combining Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To Improve Specificity for Diagnosis of Malaria Due to Plasmodium knowlesi and Other Plasmodium Species in Sabah, Malaysia
【24h】

Combining Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To Improve Specificity for Diagnosis of Malaria Due to Plasmodium knowlesi and Other Plasmodium Species in Sabah, Malaysia

机译:结合基于寄生虫乳酸脱氢酶和富含组氨酸的蛋白质2的快速检测,以提高对马来西亚沙巴的诺氏疟原虫和其他疟原虫物种造成的疟疾诊断的特异性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Plasmodium knowlesi causes severe and fatal malaria in Malaysia. Microscopic misdiagnosis is common and may delay appropriate treatment. P. knowlesi can cross-react with “species-specific” parasite lactate dehydrogenase (pLDH) monoclonal antibodies used in rapid diagnostic tests (RDTs) to detect P. falciparum and P. vivax. At one tertiary-care hospital and two district hospitals in Sabah, we prospectively evaluated two combination RDTs for malaria diagnosis by using both a pan-Plasmodium-pLDH (pan-pLDH)/P. falciparum-specific-pLDH (Pf-pLDH) RDT (OptiMAL-IT) and a non-P. falciparum VOM-pLDH/Pf-HRP2 RDT (CareStart). Differential cross-reactivity among these combinations was hypothesized to differentiate P. knowlesi from other Plasmodium monoinfections. Among 323 patients with PCR-confirmed P. knowlesi (n = 193), P. falciparum (n = 93), and P. vivax (n = 37) monoinfections, the VOM-pLDH individual component had the highest sensitivity for nonsevere (35%; 95% confidence interval [CI], 27 to 43%) and severe (92%; CI, 81 to 100%) P. knowlesi malaria. CareStart demonstrated a P. knowlesi sensitivity of 42% (CI, 34 to 49%) and specificity of 74% (CI, 65 to 82%), a P. vivax sensitivity of 83% (CI, 66 to 93%) and specificity of 71% (CI, 65 to 76%), and a P. falciparum sensitivity of 97% (CI, 90 to 99%) and specificity of 99% (CI, 97 to 100%). OptiMAL-IT demonstrated a P. knowlesi sensitivity of 32% (CI, 25 to 39%) and specificity of 21% (CI, 15 to 29%), a P. vivax sensitivity of 60% (CI, 42 to 75%) and specificity of 97% (CI, 94 to 99%), and a P. falciparum sensitivity of 82% (CI, 72 to 89%) and specificity of 39% (CI, 33 to 46%). The combination of CareStart plus OptiMAL-IT for P. knowlesi using predefined criteria gave a sensitivity of 25% (CI, 19 to 32%) and specificity of 97% (CI, 92 to 99%). Combining two RDT combinations was highly specific for P. knowlesi malaria diagnosis; however, sensitivity was poor. The specificity of pLDH RDTs was decreased for P. vivax and P. falciparum because of P. knowlesi cross-reactivity and cautions against their use alone in areas where P. knowlesi malaria is endemic. Sensitive P. knowlesi-specific RDTs and/or alternative molecular diagnostic tools are needed in areas where P. knowlesi malaria is endemic.
机译:恶性疟原虫在马来西亚引起严重和致命的疟疾。显微镜下的误诊很常见,可能会延迟适当的治疗。诺氏疟原虫可以与快速诊断测试(RDT)中使用的“物种特异性”寄生虫乳酸脱氢酶(pLDH)单克隆抗体发生交叉反应,以检测恶性疟原虫和间日疟原虫。在沙巴州的一家三级医院和两家地区医院,我们通过使用全Plasmodium-pLDH(pan-pLDH)/ P前瞻性评估了两种组合的RDT用于疟疾诊断。恶性肿瘤特异性pLDH( Pf -pLDH)RDT(OptiMAL-IT)和非P。恶性肿瘤VOM-pLDH / Pf -HRP2 RDT(CareStart)。假设这些组合之间的交叉反应性不同,以区分诺氏疟原虫与其他疟原虫单感染。在323例经PCR确诊的诺氏疟原虫( n = 193),恶性疟原虫( n = 93)和间日疟原虫( n = 37)单一感染,VOM-pLDH单个成分对非严重(35%; 95%置信区间[CI],27至43%)和严重(92%; CI,81至100%)P的敏感性最高。Knowlesi疟疾。 CareStart证明诺氏疟原虫敏感性为42%(CI,34至49%)和特异性为74%(CI,65至82%),间日疟原虫对虾的敏感性为83%(CI,66至93%)和特异性恶性疟原虫的敏感性为71%(CI为65至76%),恶性疟原虫敏感性为97%(CI为90至99%),特异性为99%(CI为97至100%)。 OptiMAL-IT证明诺氏疟原虫敏感性为32%(CI,25至39%)和特异性为21%(CI,15至29%),间日疟原虫的敏感性为60%(CI,42至75%)特异性为97%(CI为94至99%),恶性疟原虫敏感性为82%(CI为72至89%)和特异性为39%(CI为33至46%)。使用预定义的标准,将CareStart加上OptiMAL-IT用于诺氏假单胞菌的敏感性为25%(CI为19至32%),特异性为97%(CI为92至99%)。结合两种RDT组合对诺氏疟疾疟疾诊断具有高度特异性。但是,敏感性差。对于间日疟原虫和恶性疟原虫,pLDH RDTs的特异性降低,这是因为诺氏疟原虫交叉反应,并警告不要在诺氏疟原虫疟疾流行地区单独使用它们。在诺氏疟疾流行地区,需要灵敏的诺氏疟原虫特有的RDT和/或替代性分子诊断工具。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号